Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of Humana Inc (NYSE:HUM) by 0.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,124 shares of the insurance provider’s stock after acquiring an additional 178 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Humana were worth $8,517,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. Bartlett & Co. LLC acquired a new position in shares of Humana in the 1st quarter valued at about $30,000. Lighthouse Financial Advisors Inc. purchased a new position in Humana in the fourth quarter valued at approximately $31,000. Valeo Financial Advisors LLC lifted its position in Humana by 66.1% during the first quarter. Valeo Financial Advisors LLC now owns 93 shares of the insurance provider’s stock valued at $31,000 after buying an additional 37 shares in the last quarter. Sandy Spring Bank acquired a new position in Humana during the first quarter valued at approximately $32,000. Finally, 1776 Wealth LLC grew its stake in Humana by 307.7% during the first quarter. 1776 Wealth LLC now owns 106 shares of the insurance provider’s stock worth $33,000 after buying an additional 80 shares during the period. Institutional investors own 93.22% of the company’s stock.
HUM traded down $0.84 during trading on Friday, hitting $394.43. The company had a trading volume of 415,854 shares, compared to its average volume of 962,079. The company has a market cap of $52.26 billion, a PE ratio of 20.25, a P/E/G ratio of 1.73 and a beta of 0.91. The business has a 50-day moving average of $361.93 and a 200-day moving average of $345.82. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.66 and a quick ratio of 1.66. Humana Inc has a 1-year low of $208.25 and a 1-year high of $412.70.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.84 by $0.56. The company had revenue of $18.94 billion during the quarter, compared to analyst estimates of $18.49 billion. Humana had a net margin of 3.86% and a return on equity of 21.02%. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period last year, the business earned $4.48 EPS. Research analysts forecast that Humana Inc will post 18.55 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.625 dividend. This represents a $2.50 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend is Monday, June 29th. Humana’s dividend payout ratio is currently 13.99%.
In other Humana news, Director David A. Jr/Ky Jones sold 5,800 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $256.19, for a total transaction of $1,485,902.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.42% of the stock is owned by insiders.
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of Humana from $345.00 to $400.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Goldman Sachs Group restated a “buy” rating and set a $425.00 price objective on shares of Humana in a research note on Monday, January 27th. Oppenheimer increased their target price on Humana from $400.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, April 30th. SunTrust Banks raised their target price on Humana from $400.00 to $440.00 and gave the company a “hold” rating in a report on Thursday. Finally, Citigroup upped their price target on Humana from $424.00 to $435.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $405.42.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: Trading Ex-Dividend Strategy
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.